Novartis, Coartem Baby ottiene approvazione in 16 Paesi
- Novartis ha ottenuto la revisione prioritaria per l’antimalarico KLU156 (ganaplacide/lumefantrine), presentato a Swissmedic e FDA statunitense.
- Coartem Baby, trattamento antimalarico per neonati e bambini molto piccoli, ha ricevuto il via libera in 16 Paesi.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire on November 10, 2026, and is solely responsible for the information contained therein.